Sensus (SRTS) insider buys 1,000 shares at $4.26
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
Rhea-AI Filing Summary
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,000 shares
Net Buy
3 txns
Insider
Sardano Michael
Role
PRESIDENT AND GENERAL COUNSEL
Bought
2,000 shs ($9K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $4.26 | $4K |
| Purchase | Common Stock | 766 | $4.27 | $3K |
| Purchase | Common Stock | 234 | $4.24 | $992.16 |
Holdings After Transaction:
Common Stock — 117,839 shares (Direct);
Common Stock — 118,839 shares (Indirect, spouse)
Footnotes (1)
- F1. Shares held by Mr. Sardano's spouse, as to which he disclaims beneficial ownership.
FAQ
What insider transactions did SRTS report for Michael Sardano?
On November 11, 2025, he bought 1,000 shares at $4.26 directly, and his spouse purchased 766 at $4.27 and 234 at $4.24.
What roles does Michael Sardano hold at Sensus Healthcare (SRTS)?
He is President and General Counsel and also a Director.
What was the transaction type on the Form 4/A for SRTS?
Each reported entry is coded P, indicating an open‑market purchase.
When was the earliest transaction date reported for SRTS?
The earliest transaction date reported is November 11, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.